Propylallyltryptamine
Propylallyltryptamine, also known as N-propyl-N-allyltryptamine or by its developmental code name ASR-3004, is a serotonin receptor modulator of the tryptamine family. It is an asymmetrical analogue of dipropyltryptamine and diallyltryptamine. The drug is a non-selective serotonin receptor agonist, including of the serotonin 5-HT1B, 5-HT2A, 5-HT2B, and 5-HT6 receptors, but not of the serotonin 5-HT1A receptor. It is also a serotonin–norepinephrine–dopamine reuptake inhibitor. The chemical synthesis of PALT has been described. A notable analogue of PALT is iPALT. PALT was patented by the Alexander Shulgin Research Institute in 2024.